IKT-001 in pulmonary arterial hypertension

Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing IKT-001 plus stable background PAH therapy with Placebo plus stable background PAH therapy (2 arms). Primary endpoints: Part A: Change from baseline in pulmonary vascular resistance at Week 24 and Part B: Change from baseline in 6-minute walk distance at Week 24. Planned start May 2026; status: authorised.